tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

EXAI

Two new option listings and one option delisting on November 21st
The FlyTwo new option listings and one option delisting on November 21st
7M ago
EXAI
PEPG
Exscientia and Recursion Merge to Revolutionize Drug Discovery
PremiumCompany Announcements
Exscientia and Recursion Merge to Revolutionize Drug Discovery
7M ago
6K
EXAI
Recursion, Exscientia officially combine to advance drug discovery
PremiumThe Fly
Recursion, Exscientia officially combine to advance drug discovery
7M ago
EXAI
RXRX
Recursion and Exscientia Merger Approved by Shareholders
PremiumCompany Announcements
Recursion and Exscientia Merger Approved by Shareholders
7M ago
6K
EXAI
Recursion, Exscientia shareholders approve proposed combination
PremiumThe Fly
Recursion, Exscientia shareholders approve proposed combination
7M ago
EXAI
RXRX
Exscientia Plc Gains Strong Shareholder Support
PremiumCompany AnnouncementsExscientia Plc Gains Strong Shareholder Support
7M ago
6K
EXAI
EXAI Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
EXAI Upcoming Earnings Report: What to Expect?
7M ago
EXAI
Exscientia Plc Faces Financial Challenges Amid Rising Costs
Premium
Company Announcements
Exscientia Plc Faces Financial Challenges Amid Rising Costs
7M ago
6K
EXAI
Exscientia Plc Enhances Board Collaboration with Recursion
PremiumCompany Announcements
Exscientia Plc Enhances Board Collaboration with Recursion
7M ago
6K
EXAI
Exscientia advances two additional discovery programs with Sanofi
PremiumThe Fly
Exscientia advances two additional discovery programs with Sanofi
8M ago
SNY
EXAI
Exscientia Set for Strategic Acquisition by Recursion
PremiumCompany Announcements
Exscientia Set for Strategic Acquisition by Recursion
8M ago
6K
EXAI
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals
PremiumCompany Announcements
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals
10M ago
6K
EXAI
Exscientia’s Strategic Merger and Pipeline Progress
PremiumCompany AnnouncementsExscientia’s Strategic Merger and Pipeline Progress
10M ago
6K
EXAI
Exscientia reports Q2 EPS (36c) vs. (37c) last year
Premium
The Fly
Exscientia reports Q2 EPS (36c) vs. (37c) last year
10M ago
EXAI
Small Cap Stocks: Recursion Pharmaceuticals (RXRX) Applying AI and Strategic Partnerships
Premium
Market News
Small Cap Stocks: Recursion Pharmaceuticals (RXRX) Applying AI and Strategic Partnerships
10M ago
MRK
SNY
Exscientia downgraded to Equal Weight from Overweight at Barclays
PremiumThe Fly
Exscientia downgraded to Equal Weight from Overweight at Barclays
10M ago
EXAI
Is EXAI a Buy, Before Earnings?
PremiumPre-Earnings
Is EXAI a Buy, Before Earnings?
10M ago
EXAI
Exscientia Agrees to Acquisition by Recursion Pharmaceuticals
PremiumCompany Announcements
Exscientia Agrees to Acquisition by Recursion Pharmaceuticals
10M ago
6K
EXAI
Exscientia downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
Exscientia downgraded to Hold from Buy at TD Cowen
10M ago
EXAI
Recursion Pharmaceuticals to combine with Exscientia in all-stock deal
PremiumThe FlyRecursion Pharmaceuticals to combine with Exscientia in all-stock deal
10M ago
EXAI
RXRX
Exscientia price target lowered to $9 from $10 at Barclays
Premium
The Fly
Exscientia price target lowered to $9 from $10 at Barclays
11M ago
EXAI
Exscientia Secures Full Rights to Novel Cancer Drug
Premium
Company Announcements
Exscientia Secures Full Rights to Novel Cancer Drug
11M ago
6K
EXAI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >